In what Science magazine has dubbed “Novo Nordisk’s Canadian Mistake,” Ozempic is soon to come off patent in Canada, opening the door to cheaper generic copycats, after the drug giant reportedly ...

Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

Hims & Hers Health partnered with Novo Nordisk earlier this year, only for that to unravel shortly afterward due to ...

A US doctor has explained the reality behind the 'Ozempic penis' side effect men have reported having after taking the GLP-1 drug ...

Biocon aims to introduce generic versions of the obesity drug Wegovy in India and Canada by late 2026 or early 2027, ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

Hims & Hers bounced back by 8.64 percent on Monday to close at $52.03 following announcements that it remains open to working ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

A psychologist has revealed what effect Ozempic can have on a person's sex drive and how that ties into the 'reward system'. Now, people are using Ozempic to manage their weight, but its manufacturer ...

Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A ...

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...